[go: up one dir, main page]

DE69026812D1 - Konjugate von "pokeweed" antiviralem protein und monoklonalen antikörpern - Google Patents

Konjugate von "pokeweed" antiviralem protein und monoklonalen antikörpern

Info

Publication number
DE69026812D1
DE69026812D1 DE69026812T DE69026812T DE69026812D1 DE 69026812 D1 DE69026812 D1 DE 69026812D1 DE 69026812 T DE69026812 T DE 69026812T DE 69026812 T DE69026812 T DE 69026812T DE 69026812 D1 DE69026812 D1 DE 69026812D1
Authority
DE
Germany
Prior art keywords
pokeweed
conjugates
antiviral protein
monoclonal antibodies
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69026812T
Other languages
English (en)
Other versions
DE69026812T2 (de
Inventor
Fatih Uckun
Joyce Zarling
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncogen LP
University of Minnesota Twin Cities
Original Assignee
Oncogen LP
University of Minnesota Twin Cities
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncogen LP, University of Minnesota Twin Cities filed Critical Oncogen LP
Publication of DE69026812D1 publication Critical patent/DE69026812D1/de
Application granted granted Critical
Publication of DE69026812T2 publication Critical patent/DE69026812T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817Toxins
    • A61K47/6819Plant toxins
    • A61K47/6825Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Botany (AREA)
  • Cell Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69026812T 1989-07-25 1990-07-12 Konjugate von "pokeweed" antiviralem protein und monoklonalen antikörpern Expired - Fee Related DE69026812T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38531489A 1989-07-25 1989-07-25
US50352290A 1990-03-30 1990-03-30
PCT/US1990/003921 WO1991001145A1 (en) 1989-07-25 1990-07-12 Pokeweed antiviral protein - monoclonal antibody conjugates

Publications (2)

Publication Number Publication Date
DE69026812D1 true DE69026812D1 (de) 1996-06-05
DE69026812T2 DE69026812T2 (de) 1996-11-28

Family

ID=27010961

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69026812T Expired - Fee Related DE69026812T2 (de) 1989-07-25 1990-07-12 Konjugate von "pokeweed" antiviralem protein und monoklonalen antikörpern

Country Status (17)

Country Link
EP (1) EP0441917B1 (de)
JP (1) JP3109678B2 (de)
KR (1) KR920700698A (de)
AT (1) ATE137410T1 (de)
AU (1) AU631674B2 (de)
CA (1) CA2037900C (de)
DE (1) DE69026812T2 (de)
DK (1) DK0441917T3 (de)
ES (1) ES2087158T3 (de)
FI (1) FI911447A0 (de)
GR (1) GR1002180B (de)
IE (1) IE74143B1 (de)
IL (1) IL95134A (de)
NO (1) NO911174L (de)
NZ (1) NZ234607A (de)
PT (1) PT94789B (de)
WO (1) WO1991001145A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0425604U (de) * 1990-06-27 1992-02-28
GB9217124D0 (en) * 1992-08-13 1992-09-23 Antisoma Ltd Medical treatment
US6576236B1 (en) * 1994-07-01 2003-06-10 Dana Farber Cancer Institute Methods for stimulating T cell responses by manipulating a common cytokine receptor γ chain
US5919457A (en) * 1996-01-11 1999-07-06 Regents Of The University Of Minnesota TXU-5/B53-PAP antiviral biotherapeutic agent for the treatment of AIDS
JP6022538B2 (ja) 2011-04-12 2016-11-09 ノヴォ ノルディスク アー/エス 二重アシル化されたglp−1誘導体

Also Published As

Publication number Publication date
IL95134A (en) 1996-01-31
AU6140590A (en) 1991-02-22
IE74143B1 (en) 1997-07-02
IL95134A0 (en) 1991-06-10
CA2037900C (en) 1999-11-16
NZ234607A (en) 1992-10-28
NO911174D0 (no) 1991-03-22
FI911447A0 (fi) 1991-03-25
CA2037900A1 (en) 1991-01-26
GR1002180B (en) 1996-03-11
KR920700698A (ko) 1992-08-10
JPH04502625A (ja) 1992-05-14
NO911174L (no) 1991-05-24
DK0441917T3 (da) 1996-09-16
IE902593A1 (en) 1991-02-27
EP0441917A1 (de) 1991-08-21
JP3109678B2 (ja) 2000-11-20
PT94789A (pt) 1991-03-20
ATE137410T1 (de) 1996-05-15
AU631674B2 (en) 1992-12-03
GR900100550A (el) 1991-12-10
ES2087158T3 (es) 1996-07-16
WO1991001145A1 (en) 1991-02-07
PT94789B (pt) 1997-04-30
EP0441917B1 (de) 1996-05-01
DE69026812T2 (de) 1996-11-28

Similar Documents

Publication Publication Date Title
DE3585087D1 (de) Retrovirale polypeptide in zusammenhang mit menschlicher transformation.
DE69635377D1 (de) Effiziente anreicherung und detektion von ausgesäten tumorzellen
ES2067604T3 (es) Anticuerpos frente a proteina que se une a tnf i y a sus fragmentos f(ab).
DK0523395T3 (da) Seroreaktive områder på proteinerne E1 og E2 i HPV 16
NO963168L (no) Immunstimulatoriske monoklonale antistoffer
DE3852054D1 (de) Monoklonale Antikörper gegen Glycolipid-Antigene und ihre Verwendung.
DK282987D0 (da) Lagdelt immunoanalyseorgan til bestemmelse af et antigens tilstedevaerelse, og hvori der anvendes antistoffer beregnet til transport af partikler
DK98187D0 (da) Monoklonale antistoffer og antigen for human ikke-smaacellet lungecarcinoma og visse andre typer human carcinoma
DE69026812D1 (de) Konjugate von "pokeweed" antiviralem protein und monoklonalen antikörpern
FR2637897B1 (fr) Dosages immunologiques de l'azt, derives et conjugues et anticorps
ATE193534T1 (de) Benzodiazepin-derivate sowie deren konjugate mit proteinen und polypeptiden
DE69231495D1 (de) Neue cocain-derivate und protein- und polypeptid-cocain-derivate, konjugate und markierte verbindungen
AU8944291A (en) Immunoassay for the determination of anti-hiv antibodies in human samples
DE3585049D1 (de) Monoklonale antikoerper.
TR199800575T1 (en) Kemokin �-8'in k�sa formlar�.
DK0442372T3 (da) Forbedrede mærkede haptener, fremgangsmåde til deres fremstilling samt anvendelse af disse mærkede haptener ved immunoassays
ATE2048T1 (de) Isolierung von hepatitis be-antigen.
DK314886A (da) Histamin-derivat og -immunogen-konjugat, cellelinie og antistof produceret deraf samt immunbestemmelse af histamin ved hjaelp af antistoffet
AU6257486A (en) Specific mycoplasma membrane antigen and antibody and their clinical applications
KR100310413B1 (ko) 인간의자연형lgM항체
GR890100219A (el) Ανθρωπινα μονοκλωνικα αντισωματα που ειδικα αναγνωριζουν κυτταραιου λυσσας κυτταρα που παραγουν τα ιδια, διαμορφωσεις που περιε χουν τα ιδια και παραγωγη ολων αυτων.
ATE136469T1 (de) Neue verwendung eines monoklonalen antikörpers
NO922878L (no) Noeytralisering og/eller adcc-formidlende monoklonalt hiv-antistoff
DK34393D0 (da) Humant foetalt antigen 1 (fa1), anvendelse af fa1 og anti-fa1 specifikke antistoffer som biologiske principper og immunoreagenser samt kvantitive teknikker baseret herpaa

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee